Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07655284

STENT X: a Randomized Trial to Assess Stent-free Radical Cystectomy

Radical Cystectomy (RC) remains the gold standard for localized muscle-invasive bladder cancer (MIBC); however, use of ureteral stents at time of surgery remains controversial without level 1 evidence to comment on risks or benefits of their use. RC complications commonly include urinary tract infections (UTIs), pyelonephritis, ureteroileal leakage and stenosis, and can occur with either ileal conduit or orthotopic neobladder diversions. Traditionally, ureteral stents are thought to support anastomotic healing and reduce the risk of anastomotic leakage and strictures; however, emerging evidence from retrospective studies suggests that stent use may paradoxically increase rates of postoperative morbidity. This randomized, multicenter and prospective study aims to compare 30-day postoperative complication rates between stented and non-stented urinary diversions in patients undergoing RC for MIBC, in both ileal conduit or neobladder with either robotic or open approaches.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, Brazil

Loading trial locations.

About this study

Radical Cystectomy (RC) remains the gold standard for localized muscle-invasive bladder cancer (MIBC); however, use of ureteral stents at time of surgery remains controversial without level 1 evidence to comment on risks or benefits of their use. RC complications commonly include urinary tract infections (UTIs), pyelonephritis, ureteroileal leakage and stenosis, and can occur with either ileal conduit or orthotopic neobladder diversions. Traditionally, ureteral stents are thought to support anastomotic healing and reduce the risk of anastomotic leakage and strictures; however, emerging evidence from retrospective studies suggests that stent use may paradoxically increase rates of postoperative morbidity. This randomized, multicenter and prospective study aims to compare 30-day postoperative complication rates between stented and non-stented urinary diversions in patients undergoing RC for MIBC, in both ileal conduit or neobladder with either robotic or open approaches. Randomization between ureteroenteric anastomosis with or without ureteral stent placement will occur at time of surgery; the surgeon will know this information at time of surgery and the patient will be aware of the placement of stents following surgery as these are externalized and visible. The primary outcome will be complication rate in 30 days after the surgery. Secondary outcomes of this trial will include: length of stay, procedure duration, emergency room visits, patient reported pain, anastomotic leakage rate, ureteral stricture rate, post-operative nephrostomy tube placement, differences in complication rates between interrupted and running suture technique. The study will be conducted across three academic institutions: Brigham and Women's Hospital (BWH), Massachusetts General Hospital (MGH) and Instituto do Câncer do Estado de São Paulo (ICESP), Brazil.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults (> 18 years old)
  • Muscle invasive bladder cancer or non-muscle invasive bladder cancer with indication of Radical Cystectomy
  • No concomitant surgeries like nephrectomies, colectomies or removal of other organs affected by the tumor (Except standard lymph node dissections as well as in men the prostate and seminal vesicles and in women the uterus, fallopian tubes, ovaries and vagina, that are considered part of the oncological radical cystectomy.)
  • Patients who have the capacity to understand the study procedures and provide written informed consent

Exclusion criteria

  • Simultaneous surgical procedures (except those specified in the inclusion criteria that are considered part of a routine radical cystectomy)
  • History of prior urinary diversion
  • Patients who decline to participate, lack understanding of the study's purpose, or are unable to provide informed consent
  • Cystectomy for other reasons than Bladder cancer
  • Previous radiation therapy in the pelvis for any reason
  • Extremely debilitated patients, malnourished individuals, or those undergoing palliative or hygienic cystectomy

Treatment and study plan

ureteral stents

Device

standard of care single-J externalized ureteral stents to be placed at time of radical cystectomy

no ureteral stent

Device

no ureteral stents used at time of radical cystectomy

Primary outcomes

  1. Post-operative readmission rate

    Time frame: 30-days after surgery

    percent of patients re-admitted

Secondary outcomes

  1. length of stay

    Time frame: 30 days

    index hospitalization (days after surgery until discharge, excluding pre-admission if applicable)

  2. procedure duration

    Time frame: 30 days

    surgical time measured from incision to closing

  3. blood transfusion rate

    Time frame: 30 days

    percent of patients requiring blood transfusion

  4. Emergency room visits

    Time frame: 30 days

    percent of patients presenting to emergency room at least once after surgery

  5. patient reported pain on analog scale

    Time frame: 30 days

    analog 0 to 10 scale where 0 is no pain (best) and 10 is excruciating pain (worst)

  6. ureteral stricture rate

    Time frame: 30 days

    percent of patients developing ureteral stricture requiring intervention (e.g. nephrostomy tube placement)

  7. urine leak rate

    Time frame: 30 days

    percent of patients developing urine leak requiring intervention (e.g. interventional radiology procedure)

  8. pyelonephritis rate

    Time frame: 30 days

    percent of patients developing of urinary tract infection (defined by clinical sequelae of infection in setting of positive urinalysis requiring treatment with antibiotics)

Study contacts

Contact information is provided by the study sponsor or research team.

Timothy N Clinton, MD

CONTACT

[email protected]

617-732-6384

Sponsors and collaborators

Lead sponsor

Brigham and Women's Hospital

Other

Registry information

Official study title

STENT X Non-stent Genito-urinary Tract Reconstruction After Radical Cystectomy for Bladder Cancer - a Prospective, Randomized, Controlled and Multi Institutional Trial

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Jun 17, 2026
Registry last updated
Jun 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.